PEDIARIX Healthcare Professional Home

CDC Childhood Immunization Schedule

Integrating PEDIARIX
in Your Practice

PEDIARIX offers:

Trusted protection

Proven efficacy against severe/typical^* and mild^† pertussis^2–5
In 2 clinical studies with Infanrix^® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed), the DTaP component of PEDIARIX)
Immunogenicity comparable to separately administered DTaP, IPV, and HepB vaccines²
No evidence of interference with co-administered vaccines²
No significant difference in medically attended fever found in a post-marketing safety study⁶
Children in the study received 1 or more doses of PEDIARIX (n=40,000) compared with a matched historical control group who received 1 or more doses of another DTaP vaccine (n=39,232)⁶

Improved vaccination timeliness

In 2 retrospective, observational studies, the cohort receiving PEDIARIX demonstrated:
Significantly (P<.001) shorter mean delays in DTaP, HepB, and polio vaccination⁷
Higher rates of on-time^‡ vaccination for the HEDIS^®§ Combination 2^II vaccination series vs component cohort (P<.001)⁹

Tip-Lok syringes were designed with you in mind

Single unit-dose prefilled for your convenience
May help reduce the risk of medication errors
Color-coded labels
Luer-Lok^{® ¶} adapter fits virtually any needle, including OSHA-compliant safety needles

Important Safety Information
In clinical studies, adverse events in infants receiving PEDIARIX included injection-site reactions (pain, redness, or swelling), fever and fussiness. As with other vaccines, rare adverse events may occur. Administration of PEDIARIX was associated with higher rates of fever relative to separately administered vaccines (see Adverse Reactions section of the package insert). PEDIARIX is contraindicated in infants with known hypersensitivity to any component of the vaccine including yeast, neomycin, and polymyxin B. As with any vaccine, vaccination with PEDIARIX may not protect 100% of susceptible individuals.

Click Here to Download the Complete Prescribing Information for PEDIARIX.

*Severe/typical pertussis defined by the World Health Organization as the presence of paroxysmal cough ≥21 days with laboratory confirmation.
^†Mild pertussis defined as the presence of paroxysmal cough ≥7 days with laboratory confirmation.
^‡On-time rates were calculated as a percentage of children who received immunizations within the time frame recommended by the ACIP/AAP/AAFP schedule as described by Luman et al.⁸
^§The Health Plan Employer Data and Information Set.
^II4 DTaP (diphtheria and tetanus toxoids and acellular pertussis), 3 polio, 1 measles-containing vaccine (MMR), 3 HepB, 3 Hib (Haemophilus influenzae type B), and 1 varicella.
^¶Luer-Lok is a registered trademark of Becton, Dickinson and Company.

References: 1. Data on file, PED_DOF06. GlaxoSmithKline. 2. PEDIARIX prescribing information. 3. INFANRIX prescribing information. 4. Greco D, Salmaso S, Mastrantonio P, et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N Engl J Med. 1996;334:341–348. 5. Schmitt HJ, Wirsing von Konig CH, Neiss A, et al. Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA. 1996;275:37–41. 6. Data on file. GlaxoSmithKline. Study 217744/088. 2006. Available at http://ctr.gsk.co.uk/welcome.asp. 7. Data on file. GlaxoSmithKline. Pediatric combination vaccine (DTaP-HepB-IPV) and improved pediatric immunization timeliness in a southern Medicaid population. 2007. 8. Luman ET, Barker LE, Shaw KM, et al. Timeliness of childhood vaccinations in the United States: days undervaccinated and number of vaccines delayed. JAMA. 2005;293:1204–1211. 9. Happe LE, Lunacsek OE, Marshall GS, Lewis T, Spencer S. Combination vaccine use and vaccination quality in a managed care population. Am J Manag Care. 2007;13:506–512.

PEDIARIX, INFANRIX, and Tip-Lok are registered trademarks of GlaxoSmithKline.
The five-color star is a trademark of GlaxoSmithKline.
Manufactured by GlaxoSmithKline Biologicals, Rixensart, Belgium
Distributed by GlaxoSmithKline, Research Triangle Park, NC 27709